Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
Identifieur interne : 002549 ( Main/Exploration ); précédent : 002548; suivant : 002550Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
Auteurs : H. Heinonen [Finlande] ; M. Savij Rvi [Finlande] ; M. Kotila [Finlande] ; A. Hajba [Finlande] ; M. Scheinin [Finlande]Source :
- Journal of Neural Transmission - Parkinson's Disease and Dementia Section [ 0936-3076 ] ; 1993-10-01.
Abstract
Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.
Url:
DOI: 10.1007/BF02257674
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><author><name sortKey="Heinonen, H" sort="Heinonen, H" uniqKey="Heinonen H" first="H." last="Heinonen">H. Heinonen</name></author><author><name sortKey="Savij Rvi, M" sort="Savij Rvi, M" uniqKey="Savij Rvi M" first="M." last="Savij Rvi">M. Savij Rvi</name></author><author><name sortKey="Kotila, M" sort="Kotila, M" uniqKey="Kotila M" first="M." last="Kotila">M. Kotila</name></author><author><name sortKey="Hajba, A" sort="Hajba, A" uniqKey="Hajba A" first="A." last="Hajba">A. Hajba</name></author><author><name sortKey="Scheinin, M" sort="Scheinin, M" uniqKey="Scheinin M" first="M." last="Scheinin">M. Scheinin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:09AACF3CE7AC45D5646858190481A17203A07677</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1007/BF02257674</idno><idno type="url">https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001335</idno><idno type="wicri:Area/Main/Curation">001127</idno><idno type="wicri:Area/Main/Exploration">002549</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><author><name sortKey="Heinonen, H" sort="Heinonen, H" uniqKey="Heinonen H" first="H." last="Heinonen">H. Heinonen</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Savij Rvi, M" sort="Savij Rvi, M" uniqKey="Savij Rvi M" first="M." last="Savij Rvi">M. Savij Rvi</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Koskela Hospital, Helsinki, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Kotila, M" sort="Kotila, M" uniqKey="Kotila M" first="M." last="Kotila">M. Kotila</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Koskela Hospital, Helsinki, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Hajba, A" sort="Hajba, A" uniqKey="Hajba A" first="A." last="Hajba">A. Hajba</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Scheinin, M" sort="Scheinin, M" uniqKey="Scheinin M" first="M." last="Scheinin">M. Scheinin</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Pharmacology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><title level="j" type="abbrev">J Neural Transm Gen Sect</title><idno type="ISSN">0936-3076</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1993-10-01">1993-10-01</date><biblScope unit="volume">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="193">193</biblScope><biblScope unit="page" to="202">202</biblScope></imprint><idno type="ISSN">0936-3076</idno></series><idno type="istex">09AACF3CE7AC45D5646858190481A17203A07677</idno><idno type="DOI">10.1007/BF02257674</idno><idno type="ArticleID">Art4</idno><idno type="ArticleID">BF02257674</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0936-3076</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement><orgName><li>Université de Turku</li></orgName></list><tree><country name="Finlande"><region name="Finlande occidentale"><name sortKey="Heinonen, H" sort="Heinonen, H" uniqKey="Heinonen H" first="H." last="Heinonen">H. Heinonen</name></region><name sortKey="Hajba, A" sort="Hajba, A" uniqKey="Hajba A" first="A." last="Hajba">A. Hajba</name><name sortKey="Kotila, M" sort="Kotila, M" uniqKey="Kotila M" first="M." last="Kotila">M. Kotila</name><name sortKey="Savij Rvi, M" sort="Savij Rvi, M" uniqKey="Savij Rvi M" first="M." last="Savij Rvi">M. Savij Rvi</name><name sortKey="Scheinin, M" sort="Scheinin, M" uniqKey="Scheinin M" first="M." last="Scheinin">M. Scheinin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002549 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002549 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:09AACF3CE7AC45D5646858190481A17203A07677
|texte= Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
}}
| This area was generated with Dilib version V0.6.23. |  |